References
- Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest. 2017;82(5):453–461.
- Sinaii N, Plumb K, Cotton L, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril. 2008 Mar;89(3):538–545.
- Morotti M, Vincent K, Brawn J, et al. Peripheral changes in endometriosis-associated pain. Hum Reprod Update. 2014 Sep-Oct;20(5):717–736.
- Chiantera V, Abesadze E, Mechsner S. How to understand the complexity of endometriosis-related pain. J Endometr Pelvic Pain Disord. 2018;9(1):30–38.
- Hansen KA, Chalpe A, Eyster KM. Management of endometriosis-associated pain. Clin Obstet Gynecol. 2010 Jun;53(2):439–448.
- Ferrero S, Barra F, Leone RMU. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018 Jul;78(10):995–1012.
- Leyland N, Surrey E, Soliman AM, et al. Baseline burden of endometriosis-associated pain among women in two phase 3 elagolix studies [10Q]. Obstet Gynecol. 2018;131:186S–187S.
- Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017 Jul 6;377(1):28–40.
- Lamb YN. Elagolix: first global approval. Drugs. 2018 Sep;78(14):1501–1508.
- Lupron Depot Prescribing Information. US food and drug administration. [cited 2018 Apr]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020708s035lbl.pdf
- Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006 Jan;21(1):248–256.
- Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314–325.
- Ho MP, Gonzalez JM, Lerner HP, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015 Oct;29(10):2984–2993.
- Poulos C, Soliman AM, Renz CL, et al. Patient preferences for endometriosis pain treatments in the United States. Value Health. 2019 Jun;22(6):728–738.
- Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011 Jun;14(4):403–413.
- Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016 Jun;19(4):300–315.
- Wheeler JM, Knittle JD, Miller JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. Efficacy results. Am J Obstet Gynecol. 1992;167(5):1367–1371.
- Wheeler JM, Knittle JD, Miller JD. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. Assessment of safety. Am J Obstet Gynecol. 1993;169(1):26–33.
- Wang ST, Johnson SJ, Mitchell D, et al. Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019 Apr;8(5):337–355.
- Crosignani P, Olive D, Bergqvist A, et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006 Mar-Apr;12(2):179–189.
- Ács N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord. 2015;7(2):56–62.
- Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018 Nov;132(5):1252–1264.
- Agarwal SK, Foster WG, Groessl EJ. Rethinking endometriosis care: applying the chronic care model via a multidisciplinary program for the care of women with endometriosis. Int J Womens Health. 2019;11:405–410.